Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Precision BioSciencesAgenusAthira PharmaDBV TechnologiesJounce Therapeutics
SymbolNASDAQ:DTILNASDAQ:AGENNASDAQ:ATHANASDAQ:DBVTNASDAQ:JNCE
Price Information
Current Price$8.77$2.62$16.59$6.04$9.09
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.51.62.11.01.6
Analysis Score3.43.53.52.13.3
Community Score2.82.83.22.42.7
Dividend Score0.00.00.00.00.0
Ownership Score0.80.83.30.01.7
Earnings & Valuation Score0.60.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$20.00$8.00$42.50$7.25$15.50
% Upside from Price Target128.05% upside205.34% upside156.18% upside20.03% upside70.52% upside
Trade Information
Market Cap$501.14 million$536.28 million$615.82 million$663.63 million$412.63 million
Beta2.081.86N/A2.911.34
Average Volume1,013,8393,603,284397,732635,016532,704
Sales & Book Value
Annual Revenue$22.24 million$150.05 millionN/A$14.75 million$147.87 million
Price / Sales22.533.57N/A44.992.79
CashflowN/AN/AN/AN/A$2.21 per share
Price / CashN/AN/AN/AN/A4.11
Book Value$2.72 per share($1.68) per shareN/A$2.11 per share$5.25 per share
Price / Book3.22-1.56N/A2.861.73
Profitability
Net Income$-92,880,000.00$-107,660,000.00$-5,160,000.00$-172,020,000.00$56.82 million
EPS($1.91)($0.80)N/A($2.33)$1.66
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-484.81%-192.56%N/AN/AN/A
Return on Equity (ROE)-105.74%N/AN/AN/A-72.91%
Return on Assets (ROA)-53.08%-97.02%N/AN/A-59.68%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.08%N/A
Current Ratio2.92%0.85%30.75%4.28%6.60%
Quick Ratio2.92%0.85%30.75%4.22%6.60%
Ownership Information
Institutional Ownership Percentage48.57%53.35%66.68%32.49%60.48%
Insider Ownership Percentage14.30%4.70%N/A15.31%43.96%
Miscellaneous
Employees23135914311128
Shares Outstanding57.14 million204.69 million37.12 million109.87 million45.39 million
Next Earnings Date5/21/2021 (Estimated)5/6/2021 (Estimated)6/24/2021 (Estimated)N/A5/5/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific OfficerJounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer
finance.yahoo.com - April 12 at 8:23 AM
Jounce Therapeutics Presents Preclinical Data...Jounce Therapeutics Presents Preclinical Data...
benzinga.com - April 11 at 9:03 AM
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American ...Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American ...
apnews.com - April 10 at 1:34 PM
Jounce Therapeutics, Inc. (NASDAQ:JNCE) Insider Sells $136,215.00 in StockJounce Therapeutics, Inc. (NASDAQ:JNCE) Insider Sells $136,215.00 in Stock
americanbankingnews.com - April 1 at 4:20 PM
Jounce Therapeutics, Inc. (NASDAQ:JNCE) Receives Consensus Rating of "Hold" from AnalystsJounce Therapeutics, Inc. (NASDAQ:JNCE) Receives Consensus Rating of "Hold" from Analysts
americanbankingnews.com - April 1 at 6:50 AM
Jounce Therapeutics, Inc. (NASDAQ:JNCE) Sees Significant Growth in Short InterestJounce Therapeutics, Inc. (NASDAQ:JNCE) Sees Significant Growth in Short Interest
americanbankingnews.com - March 30 at 12:18 PM
Jounce Therapeutics (NASDAQ:JNCE) Stock Price Down 8.7%Jounce Therapeutics (NASDAQ:JNCE) Stock Price Down 8.7%
americanbankingnews.com - March 24 at 2:52 PM
Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment OptionJounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
finance.yahoo.com - March 12 at 12:04 PM
Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American ...Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American ...
apnews.com - March 11 at 8:54 AM
Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Association for Cancer Research Virtual (AACR) Annual MeetingJounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Association for Cancer Research Virtual (AACR) Annual Meeting
finance.yahoo.com - March 10 at 6:30 PM
Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common StockJounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock
finance.yahoo.com - March 10 at 3:27 AM
Jounce Therapeutics Announces Proposed Offering of Common StockJounce Therapeutics Announces Proposed Offering of Common Stock
finance.yahoo.com - March 9 at 5:07 PM
J.P. Morgan Maintains Their Sell Rating on Jounce Therapeutics (JNCE)J.P. Morgan Maintains Their Sell Rating on Jounce Therapeutics (JNCE)
smarteranalyst.com - March 5 at 7:45 PM
Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE)Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE)
finance.yahoo.com - March 2 at 7:56 AM
Jounce Therapeutics, Inc. (JNCE) Q4 2020 Earnings Call TranscriptJounce Therapeutics, Inc. (JNCE) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 26 at 6:03 PM
Notable Thursday Option Activity: DG, JNCE, AMCNotable Thursday Option Activity: DG, JNCE, AMC
nasdaq.com - February 25 at 5:01 PM
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial ResultsJounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 25 at 7:00 AM
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
finance.yahoo.com - February 18 at 9:21 AM
Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of DirectorsJounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
finance.yahoo.com - February 12 at 8:09 AM
Jounce Therapeutics, Inc. (NASDAQ:JNCE) On Friday – Up 78.84 Percent From Lows, What To Expect Going Ahead?Jounce Therapeutics, Inc. (NASDAQ:JNCE) On Friday – Up 78.84 Percent From Lows, What To Expect Going Ahead?
marketingsentinel.com - February 8 at 8:58 AM
JNCE Feb 2021 15.000 putJNCE Feb 2021 15.000 put
au.finance.yahoo.com - January 28 at 6:13 PM
JNCE Feb 2021 10.000 putJNCE Feb 2021 10.000 put
au.finance.yahoo.com - January 26 at 11:29 PM
JNCE Feb 2021 15.000 callJNCE Feb 2021 15.000 call
au.finance.yahoo.com - January 26 at 11:29 PM
JNCE Feb 2021 10.000 callJNCE Feb 2021 10.000 call
au.finance.yahoo.com - January 26 at 6:29 PM
Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 ...Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 ...
apnews.com - January 14 at 4:18 AM
DateCompanyBrokerageAction
3/18/2021Precision BioSciencesJonestradingReiterated Rating
1/29/2021Precision BioSciencesJPMorgan Chase & Co.Boost Price Target
12/15/2020Precision BioSciencesHC WainwrightReiterated Rating
11/23/2020Precision BioSciencesStifel NicolausBoost Price Target
8/17/2020Precision BioSciencesBarclaysReiterated Rating
6/8/2020Precision BioSciencesWilliam BlairReiterated Rating
4/2/2020Precision BioSciencesThe Goldman Sachs GroupDowngrade
8/9/2019Precision BioSciencesBTIG ResearchInitiated Coverage
4/22/2019Precision BioSciencesJefferies Financial GroupInitiated Coverage
1/15/2021AgenusB. RileyReiterated Rating
10/13/2020Athira PharmaJMP SecuritiesInitiated Coverage
3/12/2021DBV TechnologiesSVB LeerinkReiterated Rating
1/22/2021DBV TechnologiesSociete GeneraleDowngrade
1/15/2021DBV TechnologiesCitigroupBoost Price Target
8/5/2020DBV TechnologiesMorgan StanleyLower Price Target
8/4/2020DBV TechnologiesBryan, Garnier & CoDowngrade
3/20/2020DBV TechnologiesKepler Capital MarketsDowngrade
10/16/2019DBV TechnologiesOddo BhfUpgrade
3/22/2021Jounce TherapeuticsPiper SandlerInitiated Coverage
2/28/2021Jounce TherapeuticsRobert W. BairdReiterated Rating
11/10/2020Jounce TherapeuticsRoth CapitalLower Price Target
11/2/2020Jounce TherapeuticsRaymond JamesDowngrade
2/27/2020Jounce TherapeuticsCowenReiterated Rating
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.